Clinical Trials Directory

Trials / Unknown

UnknownNCT04489264

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Peking University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers

Summary

The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 \& PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.

Conditions

Interventions

TypeNameDescription
DRUGTransplant, Autologoushigh dose chemotherapy followed by autologous stem cell transplantation

Timeline

Start date
2020-11-30
Primary completion
2023-11-30
Completion
2025-11-30
First posted
2020-07-28
Last updated
2020-12-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04489264. Inclusion in this directory is not an endorsement.

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma (NCT04489264) · Clinical Trials Directory